PLIN2

Across TCGA pan-cancer cohorts, PLIN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLIN2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLIN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLIN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where PLIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.441	0.707	<.001	76	view →
COAD	DFS	Median	II,III,IV	0.877	1.000	.016	36	view →
CCRCC	OS	Tertile	III,IV	0.937	0.620	.010	29	view →
UCEC	DFS	Tertile	All	0.826	0.948	.037	2	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →
LUAD	DFS	Median	All	0.662	0.807	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLIN2–PDAC (OS)

Open the PDAC breakdown →